|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | |||||
| Restructuring charges | |||||
| Net loss | |||||
| Noncontrolling Interest | |||||
| Common Stock | |||||
| Total net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Loss on impairment of goodwill | |||||
| Loss on impairment of intangible assets | |||||
| Loss on debt extinguishment | |||||
| Depreciation and amortization | |||||
| Stock-based compensation | |||||
| Change in fair value of royalties payable | |||||
| Gain on write-off of right-of-use asset and liability | |||||
| Loss on sales and disposals of property and equipment | |||||
| Provision for credit losses | |||||
| Change in fair value of royalties payable due to related parties | |||||
| Change in fair value of convertible notes payable | |||||
| Net loss on trading debt securities | |||||
| Deferred income tax provision (benefit) | |||||
| Acquired in-process research and development | |||||
| Amortization of discount on note payable | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable | |||||
| Inventories | |||||
| Prepaid expenses and other current assets | |||||
| Lease right-of-use assets and lease liabilities | |||||
| Operating lease right-of-use assets and lease liabilities | |||||
| Current portion of royalties payable due to related parties | |||||
| Accounts payable | |||||
| Accrued expenses | |||||
| Interest payable | |||||
| Related Party | |||||
| Variable Interest Entity, Not Primary Beneficiary | |||||
| Total interest payable | |||||
| Other liabilities | |||||
| Net cash used in operating activities | |||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | |||||
| Consideration paid for the acquired in-process research and development | |||||
| Purchases of property and equipment | |||||
| Proceeds from sales of property and equipment | |||||
| Cash acquired as part of business combination | |||||
| Proceeds from the sale of trading debt securities | |||||
| Net cash provided by (used in) investing activities | |||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | |||||
| Proceeds from issuance of common stock and other equity-classified contracts from the September 2024 Public Offering, net of issuance costs | |||||
| Proceeds from issuance of Series B Convertible Preferred Stock and other equity-classified warrants, net of issuance costs | |||||
| Proceeds from issuance of common stock | |||||
| September 2024 Public Offering | |||||
| The 2024 Inducement Offer | |||||
| ATM Offering | |||||
| Total proceeds from issuance of common stock | |||||
| Payments of offering costs related to the issuance of common stock and warrants | |||||
| Proceeds from notes payable due to related parties | |||||
| Proceeds from issuance of convertible notes payable | |||||
| Payments on short-term notes payable | |||||
| Proceeds from short-term notes payable | |||||
| Proceeds from exercise of warrants | |||||
| Proceeds from issuance of common stock in connection with the employee stock purchase plan | |||||
| Payments of costs related to exercise of warrants | |||||
| Payment of costs related to the warrant repricing | |||||
| Payment of convertible promissory notes and accrued interest | |||||
| Payments of offering costs related to the private placement of securities | |||||
| Proceeds from the private placement of securities | |||||
| Net cash provided by financing activities | |||||
| NET CHANGE IN CASH AND CASH EQUIVALENTS | |||||
| CASH AND CASH EQUIVALENTS, beginning of year | |||||
| CASH AND CASH EQUIVALENTS, end of year | |||||
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | |||||
| Unpaid offering costs | |||||
| Cash payments for income taxes | |||||
| Non-cash consideration for Catheter acquisition | |||||
| Conversion of Series A Convertible Preferred Stock for common stock | |||||
| Cash paid for interest | |||||
| SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES | |||||
| Property and equipment reclassified from inventories | |||||
| Conversion of Series A Convertible Preferred Stock for common stock | |||||
| Non-cash consideration for Catheter acquisition | |||||
| Consideration for asset acquisition included in accounts payable | |||||
| Assets acquired in noncash transactions | |||||
| Stock Issued with Assets Acquisition | |||||
| Noncontrolling Interest | |||||
| Notes payable issued | |||||
| Related Party | |||||
| Asset Acquisition | |||||
| Extinguishment of notes payable due to related parties | |||||
| Noncash consideration issued in connection with extinguishment of notes payable due to related parties | |||||
| Extinguishment of royalties payable due to related parties | |||||
| Issuance of stock | |||||
| Common Stock | |||||
| Conversion of Royalties Payable into Series J Preferred Stock | |||||
| Operating right-of-use asset obtained in exchange for new operating lease liabilities | |||||
Loading...